Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating adverse events and changes in disease activity of intravenously infused Etentamig (ABBV-383) in combination with anti-cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Etentamig

Snippet

Sponsor: AbbVie | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING